Biomerica, Inc. (BMRA)

US — Healthcare Sector
Peers: SRDX  MOVE  AIMD  INVO  TIVC  BBLG  TNON  MOTS  MODD  NPCE  NXL  SSKN  NMRD    SGHT  DYNT  AZYO 

Automate Your Wheel Strategy on BMRA

With Tiblio's Option Bot, you can configure your own wheel strategy including BMRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BMRA
  • Rev/Share 0.3316
  • Book/Share 0.3232
  • PB 9.4363
  • Debt/Equity 0.0981
  • CurrentRatio 3.7623
  • ROIC -0.8398

 

  • MktCap 7764574.0
  • FreeCF/Share -0.2481
  • PFCF -1.8278
  • PE -10.7671
  • Debt/Assets 0.0736
  • DivYield 0
  • ROE -0.859

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System
BMRA
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

IRVINE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), an innovator in diagnostic-guided therapy, today announced compelling real-world results demonstrating the effectiveness of its inFoods® IBS product, along with the launch of a proprietary real-time patient feedback system to enhance symptom tracking and improve patient outcomes.

Read More
image for news Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System
PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement
BMRA
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

- Application represents milestone toward broadening patient access to inFoods IBS - inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company and its CLIA laboratory partner have submitted an application to the American Medical Association (AMA) CPT Editorial Panel requesting the assignment of a Proprietary Laboratory Analysis (PLA) code for the inFoods® IBS diagnostic test.

Read More
image for news PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement

About Biomerica, Inc. (BMRA)

  • IPO Date 1984-09-07
  • Website https://www.biomerica.com
  • Industry Medical - Devices
  • CEO Mr. Zackary S. Irani
  • Employees 64
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.